63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces

Cone, Edward J.; Gorodetzky, Charles W.; Yousefnejad, David; Darwin, William D.

doi:10.1016/0378-4347(85)80042-6

Cited by 36 publications

(14 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A factor that is worth mentioning in the present context is the N-dealkyl metabolite of buprenorphine, norbuprenorphine, which is the major metabolite of buprenorphine in humans and rats (Cone et al 1985;Ohtani et al 1989Ohtani et al , 1995. Norbuprenorphine might contribute to the effects and side-effects produced by buprenorphine administration (Ohtani et al 1995(Ohtani et al , 1997.…”

Section: Antagonism Of Buprenorphine Cpp Effectsmentioning

confidence: 99%

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Tzschentke

2004

Psychopharmacology

View full text Add to dashboard Cite

The present results suggest that the reported lack of CPP effects at high doses of buprenorphine may be due to factors in the experimental design, resulting in a carry-over effect from drug- to vehicle conditioning. They also suggest that buprenorphine, like other opiates, produces its CPP effects via micro -receptors, although kappa-antagonistic mechanisms also appear to be involved. The implications of these findings for the safety of buprenorphine for human use are discussed.

show abstract

Section: Antagonism Of Buprenorphine Cpp Effectsmentioning

confidence: 99%

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Tzschentke

2004

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Because of the low concentrations and because three analytes need to be determined for pharmacokinetic study in plasma, the sensitive, accurate, precise and efficient assay was necessary for sample bioanalysis. With the GC-MS method for quantification of BUP and NBUP, the limit of quantification in plasma was only 0.1 and 2 lg mL -1 , [21][22][23], which was insufficiently sensitive to enable full pharmacokinetic profiling of BUP and NBUP and naloxone. Moody et al [24] have reported an analytical method that can simultaneously determine BUP, NBUP and naloxone using LC-MS-MS. Full validation and application were well performed in the study; however, even though BUP and NBUP were low enough to perform concentration analysis in plasma, the LLOQ of naloxone was not sensitive enough to do the pharmacokinetic profiling.…”

Section: Discussionmentioning

confidence: 99%

“…Even though the limitation of quantification of a GC-ECD method in plasma can be 0.1 lg L -1 for BUP, NBUP and naloxone in plasma were not available for analysis with BUP in the same run using the method [22]. In the GC-MS method for quantification of BUP and NBUP, the limit of quantification in plasma was only 0.1 lg mL -1 and 2 lg mL -1 , which was insufficiently sensitive to enable full pharmacokinetic profiling of BUP and NBUP [21,23].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Determination of Buprenorphine, Norbuprenorphine and Naloxone in Human Plasma by LC-MS-MS

Chiang

Pao²,

Hsiong³

et al. 2011

Chromatographia

View full text Add to dashboard Cite

A novel sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS-MS) method simultaneously determined buprenorphine (BUP) and its active metabolite, norbuprenorphine (NBUP), and a coformulant, naloxone was developed, validated and applied successfully in humans. Buprenorphine-d 4 and norbuprenorphine-d 3 were used as the internal standard. The analysis was performed on a silica column, and the mobile phase was isocratic and composed of acetonitrile:2 mM ammonium formate in H2O (82:18, v/v). Mass spectrometry employed multiple reaction monitoring modes with transitions of m/z 468.1-55.2 for BUP, 414.2-101.2 for NBUP, 328.3-310.3 for naloxone, 472.1-59.2 for buprenorphine-d 4 and 417.2-101.2 for norbuprenorphine-d 3 . Lower limit of quantification (LLOQ) of the analytical method was 0.05 ng mL -1 for BUP, 0.1 ng mL -1 for NBUP and 0.025 ng mL -1 for naloxone, respectively. The standard calibration curves of BUP, NBUP and naloxone were linear over the concentration range of 0.05-20 ng mL -1 , 0.1-20 ng mL -1 and 0.025-20 ng mL -1 , respectively. The precisions (RSD) and accuracies (RE) of LLOQ and other QC samples were in acceptable range, with RSD \ 20% and RE ± 20% for LLOQ and RSD \ 15% and RE within ±15% for QC samples. The method was accurate, precise and specific, and was applied to the pharmacokinetic study of buprenorphine in healthy volunteers.

show abstract

“…This very low concentration level constitutes a challenging task for analysis. 5 There were various analytical methods for BP in biological specimens, such as gas chromatography (GC), 6 gas chromatography-mass spectrometry (GC-MS), [8][9][10] high-performance liquid chromatography(HPLC) 7 and high-performance liquid chromatography-mass spectrometry (HPLC-MS).…”

Section: Introductionmentioning

confidence: 99%

Development of a Rapid and Simultaneous Detection Method for Buprenorphine, Norbuprenorphine and Naloxone in Human Plasma Using Ultra‐high Performance Liquid Chromatography‐tandem Mass Spectrometer with Solid‐phase Extraction

Guo

2011

Chin. J. Chem.

View full text Add to dashboard Cite

A simultaneous method was successfully established and validated for the separation and determination of buprenorphine (BP), its primary metabolite, nor-buprenorphine (NBP) and a proposed co-formulate, naloxone (NLX) in human plasma. The method used buprenorphine-d 4 (BP-D 4 ), nor-buprenorphine-d 3 (NBP-D 3 ), naltrexone (NTX) as internal standards (ISs). 100 µL of plasma sample fortified with the ISs was cleaned up by solid-phase extraction (SPE), and was then separated on a Waters Acquity TM BEH C 18 column with gradient elution using methanol and water (containing 0.2% formic) at a flow rate of 0.25 mL•min -1 . The mass spectrometer was used for detection and was operated in the positive electrospray ionization with multiple reaction monitoring (MRM) mode. The three compounds were effectively separated in 5 min. The linear ranges of the compounds were 0.1-25, 0.25-25 and 0.05-25 ng•mL -1 for BP, NBP and NLX, respectively, with r≥0.9935. The method had high sensitivity (the limits of detection were 0.02, 0.1 and 0.01 ng•mL -1 for BP, NBP and NLX, respectively) and high recoveries (≥97.6%). The result was shown to be linear and satisfactorily met current acceptance criteria for validation of bioanalytical method: intra and inter assay precisions within the required limits of ≤25% RSD. The LOQs fulfilled the LOQ requirements: precision≤25% RSD, and was fully validated according to the State Food and Drug Administration (SFDA) regulations. The results demonstrated that ultra-high performance liquid chromatographytandem mass spectrometer (UPLC-MS/MS) with SPE was a powerful detection tool and contributed to pharmaceutical analysis in biological matrices.

show abstract

63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces

Cited by 36 publications

References 7 publications

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Simultaneous Determination of Buprenorphine, Norbuprenorphine and Naloxone in Human Plasma by LC-MS-MS

Development of a Rapid and Simultaneous Detection Method for Buprenorphine, Norbuprenorphine and Naloxone in Human Plasma Using Ultra‐high Performance Liquid Chromatography‐tandem Mass Spectrometer with Solid‐phase Extraction

Contact Info

Product

Resources

About